La Beaute Inc. Filed Primary
Proposed symbol LABI on Nasdaq Capital Market · First filed Aug 31, 2026 · CIK 2151905
Effective prospectus: S-1 Aug 31, 2026 (0002151905-26-000001) · terms available
“We are offering 10,000,000 ordinary shares of the Company pursuant to this Offering.”
What the company does
La Beaute Inc. is a California corporation incorporated on July 2, 2026, that operates as a one-stop premium medical aesthetic platform. The company integrates medical aesthetic clinical services, medical-grade functional skincare series, post-procedure repair products, and customized beauty management membership services. It aims to empower clients' aesthetic and wellness goals through expert clinical services, premium product offerings, and ongoing personalized membership support.
Use of proceeds
The Company intends to use the net proceeds for, but not limited to, business development, advertising and marketing expenses, expenses related to ongoing reporting requirements, and offering expenses. The table further specifies allocations toward potential strategic acquisition and investment opportunities, marketing and promotional campaigns and events, expanding into global markets, and general working capital.
Underwriters
The completed effective-prospectus read stated no underwriters.
Extracted from S-1 0002151905-26-000001, filed Aug 31, 2026 and verified against that filing text.
Key risk factors
-
Newly established company with execution risk
“La Beaute Inc. is a newly established company in California whose principal business is to operate a one-stop premium medical aesthetic platform integrating medical aesthetic clinical services, medical-grade functional skincare series, post-procedure repair products, and customized beauty management membership services.”
-
Highly competitive industry
“We operate in a highly competitive and rapidly evolving premium medical aesthetic and beauty services industry, and our inability to compete effectively could materially adversely affect our business.”
-
Dependence on consumer demand
“Our success depends on sustained consumer demand for medical aesthetic treatments, premium skincare, and membership services; slower-than-expected adoption or shifts in consumer preferences could significantly harm our business and results of operations.”
-
Data privacy and regulatory risks
“We face significant risks related to client privacy, personal and health data protection, cybersecurity, and evolving medical aesthetic, healthcare, and cosmetics regulations, any of which could result in substantial liabilities and reputational damage.”
-
No prior public market for shares
“Prior to this offering, our common stock has not been publicly traded or quoted on any recognized exchange or quotation system.”
-
Non-refundable investor funds
“Investors cannot withdraw funds once invested and will not be entitled to a refund.”
-
Penny stock rules may apply
“We may be subject to the penny stock rules which could make it more difficult to sell the shares of our common stock.”
-
Emerging growth company exemptions
“As long as we remain an emerging growth company, we are exempt from certain reporting requirements that are applicable to other public companies.”
Financials before the first trade
The completed SEC companyfacts import produced no qualifying full-year financial history for this filer.
Filing history
| Filed | Form | Accession | |
|---|---|---|---|
| 2026-08-31 | S-1 | 0002151905-26-000001 | View on EDGAR |
Source quotes
Offer price: “The offering price per share of our ordinary shares in this offering is to be fixed at $5.00 per share.”
Shares offered: “We are offering 10,000,000 ordinary shares of the Company pursuant to this Offering.”